Table 1 Baseline characteristics of subjects by treatment group
HPMC-treated | Dextran-treated | p | |
|---|---|---|---|
(n = 19) | (n = 37) | ||
Age, years | 26.7 ± 8.2 | 30.8 ± 10.3 | 0.12 |
Male, n (%) | 15 (78.9) | 29 (78.4) | 0.63 |
Post-Lasik Ectasia, n (%) | 1 (5.2) | 9 (24.3) | 0.08 |
Keratoconus, n (%) | 18 (94.8) | 28 (75.7) | 0.08 |
BCVA preoperative (treated eye), logMAR | 0.21 ± 0.17 | 0.31 ± 0.24 | 0.11 |
BCVA preoperative (control eye), logMAR | 0.10 ± 0.16 | 0.07 ± 0.16 | 0.45 |
Kmax preoperative (treated eye), diopters | 61.1 ± 8.7 | 57.7 ± 8.1 | 0.17 |
Kmax preoperative (control eye), diopters | 51.0 ± 3.7 | 51.0 ± 6.7 | 0.98 |